Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
BioAtla Analyst Ratings and Price Targets | NASDAQ:BCAB | Benzinga
BioAtla Inc has a consensus price target of $12.29 based on the ratings of 8 analysts. The high is $25 issued by EF Hutton on August 2, 2023. The low is $1 issued by Citizens Capital Markets on March 31, 2025. The 3 most-recent analyst ratings were released by Citizens Capital Markets, JMP Securities, and JMP Securities on March 31, 2025, September 16, 2024, and May 23, 2024, respectively. With an average price target of $3.67 between Citizens Capital Markets, JMP Securities, and JMP Securities, there's an implied 1132.12% upside for BioAtla Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Citizens Capital Markets
JMP Securities
JP Morgan
EF Hutton
BTIG
1calculated from analyst ratings
Analyst Ratings for BioAtla
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/31/2025 | Buy Now | 236.03% | Citizens Capital Markets | Reni Benjamin44% | $5 → $1 | Maintains | Market Outperform | Get Alert |
| 03/31/2025 | Buy Now | — | HC Wainwright & Co. | Arthur He33% | — | Reiterates | Neutral → Neutral | Get Alert |
| 11/13/2024 | Buy Now | — | HC Wainwright & Co. | Arthur He33% | — | Downgrade | Buy → Neutral | Get Alert |
| 09/16/2024 | Buy Now | 1580.16% | JMP Securities | Reni Benjamin44% | $5 → $5 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/23/2024 | Buy Now | 1580.16% | JMP Securities | Reni Benjamin44% | $12 → $5 | Maintains | Market Outperform | Get Alert |
| 05/15/2024 | Buy Now | 2252.23% | HC Wainwright & Co. | Arthur He33% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 03/28/2024 | Buy Now | 3932.39% | JMP Securities | Reni Benjamin44% | $12 → $12 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/27/2024 | Buy Now | 2252.23% | HC Wainwright & Co. | Arthur He33% | $10 → $7 | Maintains | Buy | Get Alert |
| 12/05/2023 | Buy Now | 3932.39% | JMP Securities | Reni Benjamin44% | → $12 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/08/2023 | Buy Now | 3260.33% | HC Wainwright & Co. | Arthur He33% | $17 → $10 | Maintains | Buy | Get Alert |
| 09/25/2023 | Buy Now | 4604.46% | JP Morgan | Brian Cheng37% | $17 → $14 | Maintains | Overweight | Get Alert |
| 08/02/2023 | Buy Now | 5612.56% | JP Morgan | Brian Cheng37% | $19 → $17 | Maintains | Overweight | Get Alert |
| 08/02/2023 | Buy Now | 3932.39% | JMP Securities | Reni Benjamin44% | → $12 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/02/2023 | Buy Now | 8300.82% | EF Hutton | Tony Butler43% | → $25 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2023 | Buy Now | 5612.56% | HC Wainwright & Co. | Arthur He33% | → $17 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | 3932.39% | JMP Securities | Reni Benjamin44% | $12 → $12 | Reiterates | Outperform → Outperform | Get Alert |
| 05/15/2023 | Buy Now | 5612.56% | HC Wainwright & Co. | Arthur He33% | → $17 | Reiterates | Buy → Buy | Get Alert |
| 05/12/2023 | Buy Now | 8300.82% | EF Hutton | Tony Butler43% | → $25 | Reiterates | Buy → Buy | Get Alert |
| 04/17/2023 | Buy Now | 8300.82% | EF Hutton | Tony Butler43% | → $25 | Maintains | Buy | Get Alert |
| 04/03/2023 | Buy Now | 6284.62% | JP Morgan | Brian Cheng37% | $23 → $19 | Maintains | Overweight | Get Alert |
| 03/28/2023 | Buy Now | 4268.43% | BTIG | Thomas Shrader40% | $68 → $13 | Maintains | Buy | Get Alert |
| 03/27/2023 | Buy Now | 3932.39% | JMP Securities | Reni Benjamin44% | $17 → $12 | Maintains | Outperform | Get Alert |
| 03/24/2023 | Buy Now | 2588.26% | Credit Suisse | Tiago Fauth40% | → $8 | Reiterates | → Neutral | Get Alert |
| 03/24/2023 | Buy Now | 8300.82% | EF Hutton | Tony Butler43% | → $25 | Reiterates | → Buy | Get Alert |
| 03/24/2023 | Buy Now | 5612.56% | HC Wainwright & Co. | Arthur He33% | $20 → $17 | Maintains | Buy | Get Alert |
| 01/05/2023 | Buy Now | 8300.82% | EF Hutton | Tony Butler43% | → $25 | Initiates | → Buy | Get Alert |
| 11/04/2022 | Buy Now | 2588.26% | Credit Suisse | Tiago Fauth40% | $4 → $8 | Maintains | Neutral | Get Alert |
| 09/15/2022 | Buy Now | 5612.56% | JMP Securities | Reni Benjamin44% | → $17 | Initiates | → Market Outperform | Get Alert |
| 08/10/2022 | Buy Now | 1244.13% | Credit Suisse | Tiago Fauth40% | $5 → $4 | Maintains | Neutral | Get Alert |
| 08/10/2022 | Buy Now | 6620.66% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $25 → $20 | Maintains | Buy | Get Alert |
| 05/05/2022 | Buy Now | 1580.16% | Credit Suisse | Tiago Fauth40% | $35 → $5 | Downgrade | Outperform → Neutral | Get Alert |
FAQ
What is the target price for BioAtla (BCAB) stock?
The latest price target for BioAtla (NASDAQ:BCAB) was reported by Citizens Capital Markets on March 31, 2025. The analyst firm set a price target for $1.00 expecting BCAB to rise to within 12 months (a possible 245.66% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BioAtla (BCAB)?
The latest analyst rating for BioAtla (NASDAQ:BCAB) was provided by Citizens Capital Markets, and BioAtla maintained their market outperform rating.
When was the last upgrade for BioAtla (BCAB)?
There is no last upgrade for BioAtla
When was the last downgrade for BioAtla (BCAB)?
The last downgrade for BioAtla Inc happened on November 13, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for BioAtla Inc.
When is the next analyst rating going to be posted or updated for BioAtla (BCAB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioAtla, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioAtla was filed on March 31, 2025 so you should expect the next rating to be made available sometime around March 31, 2026.
Is the Analyst Rating BioAtla (BCAB) correct?
While ratings are subjective and will change, the latest BioAtla (BCAB) rating was a maintained with a price target of $5.00 to $1.00. The current price BioAtla (BCAB) is trading at is $0.29, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.